文献速递淋巴瘤白血病

复发难治B细胞恶性肿瘤二次CD19 CAR-T输注后的结局相关因素

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
PubMed 文献 · Blood · 2021-01-01

该研究分析44例接受二次CD19 CAR-T输注的复发难治B细胞恶性肿瘤患者,发现二次输注后严重毒性发生率低,但完全缓解率有限;首次输注前采用氟达拉滨联合环磷酰胺清淋及二次输注剂量高于首次与更高总缓解率和更长无进展生存独立相关。

要点

  • 二次CD19 CAR-T输注后严重细胞因子释放综合征和神经毒性发生率低。
  • 二次输注后完全缓解率在CLL、NHL和ALL中分别为22%、19%和21%。
  • 首次清淋含氟达拉滨且二次剂量更高与更好缓解和更长PFS独立相关。

核心结论

  • 二次CD19 CAR-T输注后严重毒性发生率低但完全缓解率有限,首次清淋方案和二次剂量是可调整的预后相关因素。

研究设计与样本

  • 回顾性分析44例在1/2期试验(NCT01865617)中接受二次CD19 CAR-T输注的复发难治B细胞恶性肿瘤患者,包括ALL 14例、CLL 9例、NHL 21例。

主要发现

  • 二次输注后≥3级细胞因子释放综合征发生率为9%,≥3级神经毒性为11%。
  • 二次输注后完全缓解率在CLL为22%、NHL为19%、ALL为21%。
  • 二次输注后中位缓解持续时间在CLL为33个月、NHL为6个月、ALL为4个月。
  • 首次输注前在环磷酰胺基础上加用氟达拉滨及二次剂量高于首次与更高总缓解率和更长无进展生存独立相关。

临床怎么用

  • 对既往CD19 CAR-T治疗失败患者,可考虑二次输注并优化首次清淋方案(含氟达拉滨)及提高二次输注剂量以改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy has shown significant efficacy for relapsed or refractory (R/R) B-cell malignancies. Yet, CD19 CAR T cells fail to induce durable responses in most patients. Second infusions of CD19 CAR T cells (CART2) have been considered as a possible approach to improve outcomes. We analyzed data from 44 patients with R/R B-cell malignancies (acute lymphoblastic leukemia [ALL], n = 14; chronic lymphocytic leukemia [CLL], n = 9; non-Hodgkin lymphoma [NHL], n = 21) who received CART2 on a phase 1/2 trial (NCT01865617) at our institution. Despite a CART2 dose increase in 82% of patients, we observed a low incidence of severe toxicity after CART2 (grade ≥3 cytokine release syndrome, 9%; grade ≥3 neurotoxicity, 11%). After CART2, complete response (CR) was achieved in 22% of CLL, 19% of NHL, and 21% of ALL patients. The median durations of response after CART2 in CLL, NHL, and ALL patients were 33, 6, and 4 months, respectively. Addition of fludarabine to cyclophosphamide-based lymphodepletion before the first CAR T-cell infusion (CART1) and an increase in the CART2 dose compared with CART1 were independently associated with higher overall response rates and longer progression-free survival after CART2. We observed durable CAR T-cell persistence after CART2 in patients who received cyclophosphamide and fludarabine (Cy-Flu) lymphodepletion before CART1 and a higher CART2 compared with CART1 cell dose. The identification of 2 modifiable pretreatment factors independently associated with better outcomes after CART2 suggests strategies to improve in vivo CAR T-cell kinetics and responses after repeat CAR T-cell infusions, and has implications for the design of trials of novel CAR T-cell products after failure of prior CAR T-cell immunotherapies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gauthier J, Bezerra ED, Hirayama AV, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood. 2021. PMID: 32967009. doi:10.1182/blood.2020006770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。